GEM Global Yield LLC SCS signed a share purchase agreement with the existing shareholders of Taiwan‑listed Senhwa Biosciences, committing up to NT$500 million for a stake in the company. The deal injects substantial capital into a Taiwanese biotech focused on oncology and antiviral therapeutics, strengthening its pipeline and signaling investor confidence in the region’s life‑science sector. Who is involved: GEM Global Yield LLC SCS (investor), Senhwa Biosciences (TPEx: 6492) and its existing shareholders.. Likely next: The parties will satisfy customary closing conditions; after closing Senhwa is expected to allocate the proceeds to clinical development and may seek further financing upon milestone achievement.. GEM Global Yield LLC SCS has executed a share purchase agreement with the existing shareholders of Senhwa Biosciences, a Taiwan‑listed biotech focused on oncology and antiviral therapies, committing up to NT$500 million (approximately US$15 million). The transaction provides Senhwa with significant funding to advance its drug pipeline while giving GEM exposure to the Taiwanese life‑science sector. No contradictory figures or alternative interpretations appear in the source. Sectors affected: biotechnology Taiwan biotech
INTELLIGENCE
Social Pulse
AI estimate · not scraped